Entegris
This is the archived full research. Read the story
The supplier of the filters, ultra-pure chemicals and polishing pastes chipmakers use up on every wafer, and of the sealed boxes wafers travel in between steps.
The scores
Growth3/4 ↑
Growing 11.5% and accelerating, but the record is two quarters and revenue is still below where it stood in 2023.
Business quality3/4 →
Qualification is per plant and the largest customer deepened while sales fell, but the materials half is being attacked and its margin fell.
Financial position3/4 ↑
Interest still takes 42% of operating profit, but nothing is due before 2028 and free cash flow repaid $315 million in six months.
Execution record2/4 ↑
Three straight guidance beats under a new chief executive, against two years of falling revenue and a target model about to be rewritten.
Per share capture3/4 →
Share count rises 1.1% a year against 11.5% revenue growth, no convertibles and no share-funded deals, but no buyback offsets it.
Potential2/4 ↑
The prize is real and 7% of it is already held, but nothing is contracted and the next leg is other companies' capital budgets.
Risk profile3/4 ↓
Three concentrations at once: one customer at 16%, China at 21%, goodwill at 95% of equity. None resolves in a single event.
Valuation2/4 ↓
About 38 times operating profit, 134% of a three-stage value near $105 at an 8% return: full, past the 120% line.
Evidence quality3/4 →
Central claims are filed facts with four outside issuers behind the machine, but the revenue split and the margin attribution exist only on a call.
The Verdict
We rate Entegris Unattractive. It sells the filters, chemicals and polishing pastes used up in making chips, so its sales follow how many wafers factories run. Sales are recovering at a record margin, but part of that record comes from an accounting change assuming its equipment lasts longer, China is slipping and nothing is contracted, so the business is mixed. Even counting its new target of about 15% yearly growth, the price sits about 29% above our value, close to our best case. The margin that ignores the accounting change still rising would change the view.
The long caseEach newer chipmaking step needs purer materials, so suppliers sell more per wafer; Entegris must show that in a margin rising beyond what its accounting change adds.
How we weighed it
The price against our value
Against it
Price at 134% of our value
The price sits above our value and close to the bull case.
The business
Cuts both ways
Mixed
A mixed business: a record margin partly from an accounting change.
Growth against what the price assumes
In its favour
Sales are recovering and the market-growth doubt was answered.
What could go wrong
Against it
China is slipping, one customer grows larger and no purchases are contracted.
Against competitors
Cuts both ways
No filed rival compares directly; against its own normal it is dearer.
How its group is behaving
Cuts both ways
Chip-equipment names move together on news about chipmakers' spending.
The latest news and report
In its favour
The last report met our test and strengthened the business case.
The evidence under this - 10 claims
- The split appears nowhere in the 10-K or the 10-Q and nothing in the filings lets it be checked.
- Revenue fell 8.0% in 2024 and 1.4% in 2025 while wafer starts grew, which is hard to reconcile with three quarters of sales tracking wafer starts unless share or mix moved against the company.
- The company gives its reasoning in the filing - an analysis of actual asset usage, obsolescence, historical usage trends and capital plans - and the new lives are not obviously aggressive against industry practice.
- The effect is disclosed in the 10-Q, quantified per share, and repeated on the call in answer to an analyst question. It was not hidden.
- It is a non-cash change and does not touch free cash flow, which rose to $120.3M in the quarter from $47.0M.
- Adjusted profit margin excluding depreciation did still rise 0.7 points, so some of the improvement is independent of the accounting change.
- Part of the depreciation fall reflects a capital programme that ended - capital spending halved to $80.8M in the first half from $174.5M - rather than the change in estimate alone. Against that, the 10-Q puts the estimate change at $18.7M in the quarter while total depreciation fell only $16.9M year on year, so the change accounts for more than the whole net fall.
- Gross margin also rose 0.7 points sequentially from Q1 2026 to Q2 2026, a comparison the estimate change cannot flatter because it was already in both quarters.
- Reported operating income is struck after $184.4M a year of amortisation of intangibles acquired with CMC Materials, which is a real cost of the acquisition and a non-cash one; on the adjusted line the multiple is a third lower.
- The trailing four quarters include the two weakest of the last eight - Q3 and Q4 2025 - so the trailing figure understates the current run rate. Annualising Q2 2026 gives about $658M and a multiple nearer 38.
- 2026-10-06editedRe-struck at the 2026-10-05 close of $166.92 (from $143.03, +16.7%, past the 12% drift trigger) with no print, filing or confirmed development in between: price multiples move, the trailing earnings, profit and share count do not.
- 2026-10-21editedRe-struck at the 2026-10-20 close of $142.90 (from $166.92, -14.4%, past the 12% drift trigger) with no print, filing or confirmed change to the business in between: price multiples move, the trailing earnings, profit, net debt and share count do not.
The value leans on the analysts' path and margin, which this thesis has not tested name by name; at a 9% required return it is about $79.31, and the bear case of $46.90 is the downturn test.
- 2026-11-10editedre-struck at the 9 November close of $140.06; the base case is unchanged and the price is now 129% of it
- 2026-11-10editedre-valued on the owner's rules of 10 November: the return on new capital glides to its terminal level over years six to ten
- The previous model, beating the company's markets by 3 to 6 points, was not met in 2024 or 2025 when revenue fell (C46's earlier wording), so a new target is a promise, not a result.
- The 35% is an adjusted margin that leaves out acquisition amortisation of $184.4M a year, while the margin in our value (27.2%) is struck after it and after stock pay.
The company
Making a chip takes hundreds of steps, and at each one a stray molecule can ruin the wafer. Entegris sells the filters and purifiers that strip contaminants from the liquids and gases, the slurries and pads that polish each layer flat, and the sealed pods wafers wait in between steps.
A chipmaker cannot skip this; its only choice is whose filter or slurry to use. About 7,700 people make them across roughly 35 factories, backed by about 4,400 patents.
The evidence under this - 3 claims
How it makes money
It reports two halves: purity products, meaning filters and wafer pods, and materials, meaning slurries and chemicals. Both are consumed as chips are made, so they are bought again and again. Management says 75% of revenue follows wafer starts and 25% follows chipmakers' spending on equipment and new factories. Customers sign no long-term purchase commitments, only share forecasts.
The evidence under this - 3 claims
- The split appears nowhere in the 10-K or the 10-Q and nothing in the filings lets it be checked.
- Revenue fell 8.0% in 2024 and 1.4% in 2025 while wafer starts grew, which is hard to reconcile with three quarters of sales tracking wafer starts unless share or mix moved against the company.
- On the Q2 2026 call the chief executive said the company has been approached more recently to engage in more supply agreements given the demand environment, so the position may be changing.
- The 10-K also names short order-to-delivery time as a characteristic of the products, which is a reason customers do not need to commit rather than evidence of weakness.
Where the money comes from, stream by stream
| Stream | Share of sales (FY2025) | How it earns it |
|---|---|---|
| Advanced Purity Solutions | 56.3% | Filters, purifiers and contamination-control systems, and the sealed carriers wafers travel in, sold to chip fabs and the toolmakers that supply them. |
| Materials Solutions | 44.0% | Consumables used up in making chips: polishing slurries and pads, cleaning chemistries, deposition materials and specialty gases, bought per wafer. |
Who runs it
David Reeder has run Entegris since August 2025, taking over from a chief executive who had been with the company since 2001; the finance chief changed twice this year. Insiders own under 1%, and the chief executive almost none. Half the yearly bonus rides on a profit margin that slower depreciation cannot flatter, part on beating the chip market, and the share awards on the stock against other chipmakers. Nothing pays on returns from the money spent.
The evidence under this - 4 claims
Loy, the largest insider holder, retired and left the board on 31 July 2026 (S21), so the insiders still in place hold less than the group figure, and the chief executive's stake is token.
- The 2023 performance shares vested at 90% of target on a 45th-percentile return, so the plan paid near target for middling relative performance.
- Nothing pays on return on capital or per-share results, so the CMC Materials deal's return (C54) costs the plan nothing; the 2026 changes followed a lower say-on-pay vote in 2025.
Why it wins, and who could beat it
Why customers come back
A filter or slurry is approved for one process, at one factory, for one generation of chip. Swapping it means repeating that approval and risking the output of a line worth far more than the material, so the incumbent usually keeps the slot until the process retires. Taiwan Semiconductor's own annual report treats even a supplier's second factory as a separate approval.
The evidence it works: Taiwan Semiconductor went from 11% of Entegris's sales in 2023 to 16% in 2025.
The evidence under this - 2 claims
The threat
The threat lands on the polishing side. In China, Anji Microelectronics sells the same copper, tungsten and barrier slurries and calls itself a mainstream domestic supplier, and Entegris's own annual report notes buyers moving to local, cheaper supply. Qnity sells the same line to the same factories and names Entegris first among its rivals.
The evidence under this - 3 claims
- The statement is Anji's own marketing and no filed figure reachable here sizes it; Anji files on the Shanghai STAR market in Chinese and nothing is served here.
- Entegris's Materials Solutions segment profit margin was 20.9% last quarter against 21.3% a year earlier - a fall consistent with pressure, and equally consistent with the higher raw material, logistics and direct-labour costs management named instead.
The rivals: Q, LIN, DHR, and 1 more that is private, in-house or listed abroad.
Who else does this, rival by rival
| Ticker | Rival | How far along | Priced against it |
|---|---|---|---|
| Anji Microelectronics (Shanghai) Co., LtdPriced against it: Listed abroad | On sale | Listed abroad | |
| Q | Qnity Electronics, Inc.Priced against it: Same product | On sale | Same product |
| LIN | LindePriced against it: Small part of it | On sale | Small part of it |
| DHR | DanaherPriced against it: Small part of it | On sale | Small part of it |
How big it could get
How big this could get
Chipmakers bought $45.8B of materials for making wafers in 2025, within a $73.2B materials market that grew 6.8%; China alone bought $15.6B. Entegris sold $3.20B that year. Underneath, the volume keeps rising: Taiwan Semiconductor shipped about 15.0 million 12-inch wafers in 2025, up from 12.0 million in 2023.
The evidence under this - 3 claims
The results
The numbers
Sales grew 9.4% over the twelve months to Sep 2026, faster than the −1.4% in the year to Dec 2025.
Operating margin is 18%, up from 14% in the year to Dec 2023.
Running costs take 29¢ of each sales dollar, up from 22¢ in the year to Dec 2021.
Each dollar put into the business earns 7.4% a year after tax, down from 18% in the year to Dec 2021.
It turned 17% of sales into free cash, $616M over the last twelve months.
It owes $2.90B more than the cash it holds, about 3.6 years of the cash its operations bring in.
The share count rose 13% in 4.7 years, and pay in shares costs 2.1% of sales.
All the numbers
Filed figures from the company's 10-K and 10-Q, read 2026-11-10. Fiscal years end in December.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | 12 mo to Sep 2026 | |
|---|---|---|---|---|---|---|
| Size and growth | ||||||
| Sales | $2.30B | $3.28B | $3.52B | $3.24B | $3.20B | $3.52B |
| Sales growth | +24% | +43% | +7.4% | −8.0% | −1.4% | +9.4% |
| Profit | ||||||
| Gross margin | 46% | 43% | 42% | 46% | 44% | 47% |
| Operating margin | 24% | 15% | 14% | 16% | 14% | 18% |
| Net margin | 18% | 6.4% | 5.1% | 9.0% | 7.4% | 11% |
| What growth costs, per sales dollar | ||||||
| Research and development | 7.3% | 7.0% | 7.9% | 9.8% | 10% | 9.2% |
| Selling, general and admin | 13% | 17% | 16% | 14% | 14% | 14% |
| Pay in shares | 1.3% | 2.0% | 1.7% | 2.0% | 2.2% | 2.1% |
| Capital spending | 9.2% | 14% | 13% | 9.7% | 9.4% | 5.2% |
| Cash | ||||||
| Cash from operations | $400M | $363M | $644M | $632M | $695M | $798M |
| Free cash flow | $190M | −$103M | $188M | $316M | $396M | $616M |
| Balance sheet | ||||||
| Cash and short-term investments | $403M | $563M | $457M | $329M | $360M | $356M |
| Debt | $937M | $5.78B | $4.58B | $3.98B | $3.70B | $3.26B |
| Net cash | −$534M | −$5.22B | −$4.12B | −$3.65B | −$3.34B | −$2.90B |
| Returns and shares | ||||||
| Return on capital | 18% | 7.0% | 5.9% | 6.2% | 5.5% | 7.4% |
| Shares (diluted) | 137M | 143M | 151M | 152M | 152M | 154M |
What growth costs
Growth has been getting more expensive. Since 2020 research spending and stock pay grew far faster than sales, so each dollar of sales kept less profit, and the big acquisition added a yearly accounting charge. This year's recovery is clawing some of that back.
The evidence under this - 2 claims
- Part of the fall in operating margin is acquisition amortisation, $184.4M or 5.8% of 2025 sales (C23), an accounting charge for the CMC Materials deal rather than a cost of growing.
- Revenue fell in 2024 and 2025 (C13), so part of the rise in research per sales dollar is a shrinking denominator; the 2026 recovery has already cut it back.
The last report (29 Oct)
Quarter ended September 2026, filed figures.
The third quarter of 2026 was a beat: sales grew 24.6% to $1,005.7M against a guide of $905M to $935M, and profit before depreciation reached 30.2% of sales, a margin lower depreciation cannot flatter.
The doubt from the second quarter eased. Materials grew 15.9%, and management said revenue tied to chip volumes grew about 20% against wafer growth near 8%. Backlog rose over 35% in the quarter and the fourth quarter is guided up again.
What it did to the thesisIt met the test we set and answered the market-growth doubt, so the business case is stronger. The price question it did not touch: the shares still sit far above the company's own long-run average.
The quarter in detail
Sales growth from the previous quarter, filed figures. The company has restated its own history, so a quarter either side of the restatement may describe a different business; n/c marks one that does not compare.
Earnings per share $1.23 against $1.03 expected.
The evidence under this - 5 claims
Adjusted figures exclude items GAAP includes; GAAP diluted earnings were $1.03 against $1.23 adjusted (S24).
Direct factory headcount rose 30% on the year and inventory was built up to meet demand, so a demand slowdown would leave the company with higher fixed costs (S24).
- Management said part of the gain is higher industry volume and part is more Entegris content; it did not split the two (S24).
- Growth over wafer starts is the company's own stated model of 3 to 6 points, so beating it is the plan, not a surprise (S24).
- 2026-10-29editedre-struck on the Q3 call: materials growth now above wafer starts, where Q2 was in line
- The company beat its own guidance in each of the last four quarters, so the range is likely conservative (S23).
- The Q1 guide of a mid-single-digit sequential decline lands after a quarter that built inventory and pulled in backlog, so growth could slow faster than the year-on-year figure suggests (S24).
- 2026-10-29editedQ3 guidance was beaten on every line; re-struck to the Q4 guide given on the call
- Adjusted profit margin excluding depreciation did still rise 0.7 points, so some of the improvement is independent of the accounting change.
- Part of the depreciation fall reflects a capital programme that ended - capital spending halved to $80.8M in the first half from $174.5M - rather than the change in estimate alone. Against that, the 10-Q puts the estimate change at $18.7M in the quarter while total depreciation fell only $16.9M year on year, so the change accounts for more than the whole net fall.
- Gross margin also rose 0.7 points sequentially from Q1 2026 to Q2 2026, a comparison the estimate change cannot flatter because it was already in both quarters.
What management did with the money
Debt came down to $3.46B from $3.70B at the end of 2025. Spending on plants halved, lifting free cash flow to $120.3M in the quarter from $47.0M. There was no buyback, and the share count rose 1.1%.
The evidence under this - 3 claims
The price, and where we disagree
In short. Full. The price is about 134% of what we think the business is worth, at an 8% yearly return.
The shares have returned 57.1% over the past year and sit 23.6% below their high. Analysts expect $1.05 a share for the September quarter, above the top of the company's own $0.96 to $1.04 range, so the bar is already raised.
On 29 October the results met the test we set. On 9 November the investor day set a target of about 15% yearly sales growth, a $500 million buyback and a 10% higher dividend; the next test is the fourth-quarter results in February.
The evidence under this - 5 claims
- 2026-10-06editedRe-struck at the 2026-10-05 close of $166.92 (from $143.03, +16.7%, past the 12% drift trigger) with no print, filing or confirmed development in between: price multiples move, the trailing earnings, profit and share count do not.
- 2026-10-21editedRe-struck at the 2026-10-20 close of $142.90 (from $166.92, -14.4%, past the 12% drift trigger) with no print, filing or confirmed change to the business in between: price multiples move, the trailing earnings, profit, net debt and share count do not.
- The company beat its own guidance in each of the last four quarters, so the range is likely conservative (S23).
- The Q1 guide of a mid-single-digit sequential decline lands after a quarter that built inventory and pulled in backlog, so growth could slow faster than the year-on-year figure suggests (S24).
- 2026-10-29editedQ3 guidance was beaten on every line; re-struck to the Q4 guide given on the call
- 2026-11-10editedthe investor day was held; the targets are read in C61
- 2026-11-10editednow a held event, sourced to the 8-K furnished for it (S27); the targets themselves are C61
- The previous model, beating the company's markets by 3 to 6 points, was not met in 2024 or 2025 when revenue fell (C46's earlier wording), so a new target is a promise, not a result.
- The 35% is an adjusted margin that leaves out acquisition amortisation of $184.4M a year, while the margin in our value (27.2%) is struck after it and after stock pay.
How we value it
- Method
- Cash the business will produce, in three stages
- Required return
- 8%
- Long-run growth
- 4%
- Moat
- An average moat
| Bear | Base | Bull | |
|---|---|---|---|
| Sales growth, years 1 to 3 | 9.3%, 6.2%, 4.1% | 18.6%, 12.4%, 8.2% | 23.2%, 15.5%, 10.3% |
| Normal operating margin | 21.7% | 27.2% | 29.9% |
| Return on new capital after year ten | 8% | 12% | 15% |
| Value a share | $46.90 | $105 | $145 |
- Price
- $140
- Priced on
- 9 Nov
- Price as a share of the base value
- 134%
- Starting growth the price pays for
- 26.2%
- Yearly return the price offers on the base case
- 7.1%
- Risk check: valued at 10%, the rate for a cyclical or indebted business
- $62.26
Where each figure comes from
| Figure | Source | Where exactly |
|---|---|---|
| Sales, the last twelve months | Filed report | Quarterly report (10-Q) for the period to 26 Sep 2026, filed 29 Oct 2026; the four quarters to that date. |
| Operating margin today | Filed report | Quarterly report (10-Q) for the period to 26 Sep 2026, filed 29 Oct 2026; the four quarters to that date. |
| Tax rate | Filed report | Quarterly report (10-Q) for the period to 26 Sep 2026, filed 29 Oct 2026; the four quarters to that date. |
| Sales per dollar of new capital | Filed report | Annual report (10-K) for the period to 31 Dec 2025, filed 11 Feb 2026: the year's sales over its operating capital. |
| Shares | Filed report | Quarterly report (10-Q) for the period to 26 Sep 2026, filed 29 Oct 2026; the diluted share count. |
| Cash and investments | Filed report | Quarterly report (10-Q) for the period to 26 Sep 2026, filed 29 Oct 2026; the balance sheet on that date. |
| Debt | Filed report | Quarterly report (10-Q) for the period to 26 Sep 2026, filed 29 Oct 2026; the balance sheet on that date. |
| Sales growth, years 1 to 3 | Analysts' forecasts | FMP's consensus for the years to 31 Dec 2026, 31 Dec 2027 and 31 Dec 2028, as it stood when the value was struck on 10 Nov 2026: the average of 5 to 10 analysts' revenue estimates, 18.6%, 12.4%, 8.2%. FMP publishes how many analysts, not who they are. |
| Normal operating margin | Analysts' forecasts | FMP's consensus operating margin for the year to 31 Dec 2028, the average of 10 analysts' estimates, 29.2%, less stock pay of 2.1% of sales. FMP publishes how many analysts, not who they are. |
| Return on new capital after year ten | Our method's rule | Set by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate. |
| The bear and bull cases | Our method's rule | Our method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin. |
| Price | Market price | FMP's closing price on 9 Nov 2026. |
What each case rests on
Bear caseGrowth runs at half the analysts' path, 9%, 6% and 4%, the margin settles a fifth lower at 21.7%, and new capital earns only the 8% rate: the downturn test.
Base caseRevenue grows 19%, 12% and 8% over three years, the analysts' path (C59), then fades toward 4%, closing 30% of the gap each year; the margin moves to 27.2%, the analysts' year-three figure after stock pay.
Bull caseGrowth runs a quarter above the analysts' path, 23%, 16% and 10%, the margin reaches 29.9%, and new capital earns 15%.
What moves the base value
| Lower | Higher | |
|---|---|---|
| Growth in years 1 to 3, a quarter lower or higher | $93.00 | $118 |
| The normal margin, 15% lower or higher | $85.90 | $124 |
| Capital per dollar of growth, a quarter more or less | $101 | $107 |
| Return on new capital after year ten, at the rate or one step up | $79.99 | $115 |
| The rate, a point higher or lower | $79.31 | $148 |
| Long-run growth a point lower | $92.68 | - |
Value a share as growth and margin change
| Normal margin ↓ · growth → | 50% | 75% | 100% | 125% | 150% |
|---|---|---|---|---|---|
| 21.8% | $62.28 | $70.51 | $79.57 | $89.50 | $100 |
| 24.5% | $72.23 | $81.76 | $92.23 | $104 | $116 |
| 27.2% | $82.19 | $93.00 | $105 | $118 | $132 |
| 29.9% | $92.14 | $104 | $118 | $132 | $148 |
| 32.6% | $102 | $115 | $130 | $146 | $164 |
Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.
How we read the multiple
Buyers pay 71.7 times a year's earnings, against its own six-year normal of 48.5. Counting debt, the whole company costs about $47 for each $1 of operating profit. That assumes the recovery keeps compounding at record margins.
Two costs from past purchases weigh on the earnings underneath: $184.4M a year written off the value of what was bought, and $199.8M a year of interest on the debt that paid for it.
Against its own history. Dearer than its own normal, at a moment when part of the profit it is priced on comes from longer assumed equipment lives.
The evidence under this - 5 claims
- Reported operating income is struck after $184.4M a year of amortisation of intangibles acquired with CMC Materials, which is a real cost of the acquisition and a non-cash one; on the adjusted line the multiple is a third lower.
- The trailing four quarters include the two weakest of the last eight - Q3 and Q4 2025 - so the trailing figure understates the current run rate. Annualising Q2 2026 gives about $658M and a multiple nearer 38.
- 2026-10-06editedRe-struck at the 2026-10-05 close of $166.92 (from $143.03, +16.7%, past the 12% drift trigger) with no print, filing or confirmed development in between: price multiples move, the trailing earnings, profit and share count do not.
- 2026-10-21editedRe-struck at the 2026-10-20 close of $142.90 (from $166.92, -14.4%, past the 12% drift trigger) with no print, filing or confirmed change to the business in between: price multiples move, the trailing earnings, profit, net debt and share count do not.
- The trailing window contains the trough of the company's own cycle, so a multiple struck on it overstates how demanding the price is against normalised earnings.
- The six-year median spans 2020 to 2025, which includes both the pandemic-era peak and the post-CMC leverage trough; it is a wide and not obviously stable comparison.
- 2026-10-06editedRe-struck at the 2026-10-05 close of $166.92 (from $143.03, +16.7%, past the 12% drift trigger) with no print, filing or confirmed development in between: price multiples move, the trailing earnings, profit and share count do not. The multiples are the pack's 9 September figures scaled to the new close (earnings per share and profit before depreciation held).
- 2026-10-21editedRe-struck at the 2026-10-20 close of $142.90 (from $166.92, -14.4%, past the 12% drift trigger) with no print, filing or confirmed change to the business in between: price multiples move, the trailing earnings, profit, net debt and share count do not. The multiples are the pack's 9 September figures carried to the new close (earnings per share and profit before depreciation held).
The value leans on the analysts' path and margin, which this thesis has not tested name by name; at a 9% required return it is about $79.31, and the bear case of $46.90 is the downturn test.
- 2026-11-10editedre-struck at the 9 November close of $140.06; the base case is unchanged and the price is now 129% of it
- 2026-11-10editedre-valued on the owner's rules of 10 November: the return on new capital glides to its terminal level over years six to ten
Priced against its rivals
Only Qnity Electronics sells the same thing to the same buyers as a large part of what it does. Linde and Danaher do too, but as a small part of much bigger companies, so their price says little about this one. A price comparison needs at least two, so the price is judged against its own history instead.
Private or foreign rivals that cannot be priced: EMD Performance Materials division of Merck KGaA, Shin-Etsu Polymer Co. Ltd., Electronics Advanced Materials division of Air Liquide, Gudeng Precision Industrial, Anji Microelectronics (Shanghai) Co., Ltd, Mersen, Cobetter Filtration, Aicello Corporation.
Where we disagree with the market
A steadier way to own the chip build-out, now turning up with a spending wave and permanently higher margins.
The recovery is real, but the earnings are lower quality than the price assumes: an accounting change, no contracts, one growing half.
The company prints two margin measures side by side. The one that counts depreciation rose 3.2 points since 2025; the one that ignores it rose 0.7. The gap is exactly the fall in depreciation, and the adjusted earnings figure keeps it in.
We are wrong if the margin that ignores depreciation keeps climbing through 2027 and the materials half grows faster than wafer starts.
What analysts say, and the evidence
The evidence under this - 4 claims
- Adjusted profit margin excluding depreciation did still rise 0.7 points, so some of the improvement is independent of the accounting change.
- Part of the depreciation fall reflects a capital programme that ended - capital spending halved to $80.8M in the first half from $174.5M - rather than the change in estimate alone. Against that, the 10-Q puts the estimate change at $18.7M in the quarter while total depreciation fell only $16.9M year on year, so the change accounts for more than the whole net fall.
- Gross margin also rose 0.7 points sequentially from Q1 2026 to Q2 2026, a comparison the estimate change cannot flatter because it was already in both quarters.
- Management expects Materials Solutions to grow more than 10% year over year in both remaining quarters of 2026, so a single quarter's 4.6% may be a comparison effect rather than a trend.
- The company attributed the flat Materials Solutions margin to higher raw material and logistics costs and to planned investment in direct labour, not to price.
- Management said part of the gain is higher industry volume and part is more Entegris content; it did not split the two (S24).
- Growth over wafer starts is the company's own stated model of 3 to 6 points, so beating it is the plan, not a surprise (S24).
- 2026-10-29editedre-struck on the Q3 call: materials growth now above wafer starts, where Q2 was in line
What could go wrong, and how we would know
The risks
- China slipping. China sales fell 2% in 2025 to $657.7M, while buyers there shift toward local, cheaper suppliers such as Anji.
- One customer growing bigger. The share gain that shows the moat also concentrates risk: Taiwan Semiconductor is 16% of sales, and the top ten customers 50%, up from 43%.
- Nothing is contracted. Customers share forecasts but commit to no long-term purchases, so nothing protects sales if the chip cycle turns.
- A higher tax bill. The tax rate rose to 15.0% from 5.0% a year earlier, and a global minimum tax makes 15% the floor.
The evidence under this - 6 claims
- The 10-K attributes the China fall to lower demand for Advanced Purity Solutions products partly offset by higher Materials Solutions demand, which is the reverse of what a polishing-slurry substitution story would predict.
- Revenue is reported by ship-to location, so a Chinese fab supplied through a Taiwanese or Singaporean entity would not appear in the China row.
- The statement is Anji's own marketing and no filed figure reachable here sizes it; Anji files on the Shanghai STAR market in Chinese and nothing is served here.
- Entegris's Materials Solutions segment profit margin was 20.9% last quarter against 21.3% a year earlier - a fall consistent with pressure, and equally consistent with the higher raw material, logistics and direct-labour costs management named instead.
- On the Q2 2026 call the chief executive said the company has been approached more recently to engage in more supply agreements given the demand environment, so the position may be changing.
- The 10-K also names short order-to-delivery time as a characteristic of the products, which is a reason customers do not need to commit rather than evidence of weakness.
What we still do not know
- Whether the factory-building sales promised for 2027 arrive. A quarter of revenue depends on chipmakers' capital spending, and none of it is contracted.
- How much of the record margin survives once the equipment-lives change is in both years being compared.
The evidence under this - 4 claims
- The split appears nowhere in the 10-K or the 10-Q and nothing in the filings lets it be checked.
- Revenue fell 8.0% in 2024 and 1.4% in 2025 while wafer starts grew, which is hard to reconcile with three quarters of sales tracking wafer starts unless share or mix moved against the company.
- Management declined to split the figure between consumable and capital-spending-driven demand, and said only that it is more than $1 billion and broad-based, so it cannot be tested against either half.
- Unlocking it is already costing money: direct labour was raised more than 20% since the end of 2025, and adjusted operating expenses rose to $203.9M in Q2 2026 from $187.9M in Q4 2025 with $211M to $219M guided for Q3.
- The company gives its reasoning in the filing - an analysis of actual asset usage, obsolescence, historical usage trends and capital plans - and the new lives are not obviously aggressive against industry practice.
- The effect is disclosed in the 10-Q, quantified per share, and repeated on the call in answer to an analyst question. It was not hidden.
- It is a non-cash change and does not touch free cash flow, which rose to $120.3M in the quarter from $47.0M.
- Adjusted profit margin excluding depreciation did still rise 0.7 points, so some of the improvement is independent of the accounting change.
- Part of the depreciation fall reflects a capital programme that ended - capital spending halved to $80.8M in the first half from $174.5M - rather than the change in estimate alone. Against that, the 10-Q puts the estimate change at $18.7M in the quarter while total depreciation fell only $16.9M year on year, so the change accounts for more than the whole net fall.
- Gross margin also rose 0.7 points sequentially from Q1 2026 to Q2 2026, a comparison the estimate change cannot flatter because it was already in both quarters.
What would change our view
- Unattractive→NeutralThe price falls back inside the margin of safety
It needs:
- ○The share price falls back to about $126, 120% of what we think the business is worth.about ≈$127.56 today, 10% below the last close
- Unattractive→NeutralThe business is worth more than we count
It needs:
- ○Fourth-quarter results and the first-quarter outlook lift our value to about $117: growth stays above wafer starts and the margin ignoring depreciation holds at 29%.checked at the next results, due by 9 Feb
We would also be wrong if
- The margin excluding depreciation never passes 29% in any quarter through 2027.
- The materials half grows slower than wafer starts for three more quarters.
What is coming
- 9 November 2026 Investor day with a rewritten target model: Whether the new chief executive raises or resets the beat-the-market model missed in 2024 and 2025, and what he says about advanced packaging and spending priorities.
Every dated event ahead
- 9 November 2026 Investor day with a rewritten target model: Whether the new chief executive raises or resets the beat-the-market model missed in 2024 and 2025, and what he says about advanced packaging and spending priorities.
- February 2027 Q4 2026 results and the 2026 annual report: Whether net leverage ends 2026 in the high two times as guided, free cash flow margin holds, and Taiwan Semiconductor and China concentrations move.
Since we wrote this
- 10 NovPrice moveThe price rose through our 120% line; view moved to UnattractiveA 9% one-day rise to $140.06 after the Capital Markets Day put the shares 29% above our value of $109, so the view moved from Neutral to Unattractive.
- 9 NovThesis reviewStill Neutral: priced at 118% of a value near $109Re-valued in three stages at an 8% return, the method now drawn on every thesis: the price sits inside the 20% margin of safety.
- 29 OctEarningsQ3 2026: guidance beaten, growth above wafer startsQ3 2026 results and the earnings call
- 21 OctPrice moveRe-struck after a 14.4% fall, view unchangedThe shares fell with no new results, so a dollar of operating profit now costs about $47 instead of $54; the sale of a small life sciences unit changes nothing in the case.
- 6 OctPrice moveRe-struck after a 16.7% rise, view unchangedThe shares rose with no new results, so a dollar of operating profit now costs about $54 instead of $47; the 29 October results are still the test.
- 5 OctThesis reviewThe long case now sits under the verdictAfter the five-name pilot, the owner asked for the long case on every thesis.
- 4 OctThesis reviewOwner's checklist: revenue streams, cost of growth, management, catalystsThe owner's checklist found the method silent on who runs the company, what growth costs, where the money comes from and what is dated ahead; this pass fills those four blocks from the proxy and filings.
- 9 SepThesis writtenNeutral, medium convictionWritten five weeks after the June-quarter results lifted the shares 15.5% in a session, with a rewritten long-term target due at November's investor day.
Also checked 4 times with nothing new to act on.
Sources 27
Sources - 27
Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.
- S01primarycompany filing2026-02-11the two-segment structure and both segments' three-year sales and profit; the competitor table; the customer concentration table showing Taiwan Semiconductor at 16%; geographic revenue; the full-year income statement and non-GAAP reconciliation; cash taxes paid by jurisdiction; the non-binding order forecast language; patents, headcount and the divestiture historybacksC01C03C05C06C08C12C13C14C23C24C25C39C40C45C47C48C49C54C55C56
- S02primarycompany filing2026-08-04the change in estimated useful lives, the new life ranges by asset class and its quantified effect on depreciation, net income and earnings a share; the effective tax rate reconciliation and the global minimum tax note; the debt note with every instrument, rate and maturity; the future amortisation schedulebacksC15C26C56
- S03primarycompany filing2026-08-04the quarter's income statement, balance sheet and cash flow statement; the segment tables; Q3 2026 guidance on both basesbacksC16C20C28C30C31C33
- S04primarycompany filing2026-08-04the seven-quarter series that made the argument possible - adjusted operating margin beside adjusted profit margin excluding depreciation, and depreciation by quarter; both segments' adjusted quarterly margins; the guidance reconciliationbacksC19C21C24C30
- S05primarytranscript2026-08-06Entegris Q2 2026 earnings call transcriptmanagement's answers on the useful-life effect, the revenue split between wafer starts and capital spending, the end-market mix, the capacity claim and the leverage path; nine analysts' questions, which are a separate origin from the answers and produced the useful-life admission
As a reminder, 75% of our revenue is driven by wafer starts and 25% by CapEx. Within CapEx, 10% is driven by WFE and 15% by fab construction.
backsC02C17C29C41C42C47 - S06primarycompany filing2026-02-10the Q4 2025 reported diluted earnings of $0.32 that the tagged quarterly data does not carry, and the Q1 2026 guidance the year was framed againstread, but no claim rests on it
- S07secondaryvendor data2026-09-09Research pack, ENTG, 9 September 2026price, market value, enterprise value, the trailing multiples against their six-year medians, the returns and volatility, the analyst panel, short interest from FINRA, the insider window and the consensus estimate for Q3 2026backsC33C34C36C37
- S08primarycompany filing2026-04-16the customer's own account of qualifying suppliers' dual-plant materials; wafers shipped in 12-inch equivalents for three years; the 3-nanometer share of wafer revenue; annual capacitybacksC04C10
- S09primaryindustry data2026-05-12the size of the market from outside the company, split between the half Entegris sells into and the half it barely touches, with the regional split that frames the China finding
Global semiconductor materials market revenue increased 6.8% year-over-year to $73.2 billion in 2025. Wafer fabrication materials revenue increased 5.4% to $45.8 billion. Packaging materials revenue grew 9.3% to $27.4 billion in 2025. China ranked second at $15.6 billion, supported by double-digit growth.
backsC09 - S10primarycompany filing2026-02-26a competitor's own description of the same polishing and cleaning products sold to the same fabs, and its competition section naming Entegris firstbacksC08C45
- S11primarycompany filing2026-09-09Anji Microelectronics Technology (Shanghai) - company profile Anji Microelectronicsthe attacker's own account of its product range, its buyers and its position in China - the only primary evidence on the substitution reachable here
copper CMP slurries, barrier CMP slurries, dielectric (both silica-based and ceria-based abrasive) CMP slurries, tungsten CMP slurries, substrate CMP slurries, functional electronic wet chemicals, electroplating solution and its additives. It holds a mainstream supplier position in the domestic market and is strengthening the layout of overseas markets.
backsC07 - S12primarycompany filing2026-02-24Pall's own description of filtration serving microelectronics, and the 2025 statement that filtration core sales rose on microelectronics demand - used to test the cohort perimeterbacksC45
- S13primarycompany filing2026-02-25electronic and specialty gases among its process gases, electronics as one of six end-markets, $33,986M of 2025 sales and no electronics segment - the perimeter judgementbacksC45
- S14primarycompany release2026-08-18the company's account of patent decisions in Taiwan and China on its colloidal-silica polishing technology. The release itself returns 403 to every non-browser client; the substance was read through search results and is treated as a management claim accordinglybacksC44
- S15primarycompany filing2026-08-12the transaction code itself - S, an open-market sale of 2,062 shares at $149.52, with 66,976 retained - checked rather than read off the pack's aggregatebacksC40
- S16primarycompany release2026-08-26Entegris to host investor day on 9 November 2026the date of the investor day at which the target model is to be rewrittenread, but no claim rests on it
- S17primarycompany filing2023-02-23the terms of the CMC Materials acquisition closed 6 July 2022 and how it was financed; the 2020 to 2022 income and cash flow statements behind the numbers cardbacksC54C55C56
- S18primarycompany filing2026-03-23beneficial ownership as of 20 March 2026 and the holders above 5%; the leadership transition; the 2025 incentive plan's metrics, weights and 69.0% payout; the long-term award mix, the 2023 PSU vesting and the changes for 2026backsC50C51C52
- S19primarycompany filing2026-01-20Linda LaGorga ceasing as chief financial officer on 28 February 2026 and Michael Sauer serving as interim from 1 March 2026backsC53
- S20primarycompany filing2026-04-30Sukhi Nagesh's appointment effective 18 May 2026, his prior roles and his offer letterbacksC53
- S21primarycompany filing2026-07-29Bertrand Loy retiring as executive chair and leaving the board on 31 July 2026; James Gentilcore appointed chairbacksC52
- S22primarycompany filing2026-05-11Daniel Woodland retiring on 1 June 2026 and Olivier Blachier succeeding him as president of Materials SolutionsbacksC53
- S23primarycompany filing2026-10-29third-quarter sales, margins and earnings against the guided rangesbacksC22C32C57
- S24primarytranscript2026-10-29Q3 2026 earnings call transcript (FMP)data/cache/transcripts/ENTG-2026Q3.jsonunit growth against wafer starts, backlog, and the fourth-quarter guide; analysts' questions are a separate origin from the answers
Unit-driven revenue accelerated from approximately 6% in the first quarter to 20% in the third quarter
backsC22C32C58 - S25primarycompany filing2026-11-09trailing revenue, operating profit, stock pay, tax, debt, cash and the diluted share countbacksC60
- S26secondaryvendor data2026-11-09the analysts' average revenue and operating profit for the next three fiscal years, and the closebacksC59C60
- S27primarycompany filing2026-11-09the long-term revenue, margin and earnings targets and the new $500 million buybackbacksC46C61